FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL - Takeaway - MDSpire
Clinical Guidelines

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

The CAR T-cell therapy brexucabtagene autoleucel (Tecartus) was issued full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval now includes efficacy, safe...

Share

  • 1

    FDA has fully approved brexucabtagene autoleucel for MCL.

  • 2

    Approval based on ZUMA-2 study data.

  • 3

    High response rate (91%) in cohort 3, BTK inhibitor-naive patients.

  • 4

    MCL primarily affects older adults (>60 years).

  • 5

    Cytokine-release syndrome reported in 93% of patients.

  • 6

    Treatment demonstrates durable efficacy and manageable safety profile.

  • 7

    33,000 new MCL diagnoses annually worldwide.

  • 8

    Cohort size: 168 patients across all cohorts.

Original Source(s)

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

  • by The ASCO Post Staff

  • April 3, 2026

Related Content

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

Turning Proteins into DNA for Ultra-Sensitive Sequencing

Stanford researchers repurpose DNA sequencing technology to read proteins at single-molecule resolution, complementing – and potentially surpassing – mass spectrometry

  • April 2, 2026

  • 2 min